These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

430 related articles for article (PubMed ID: 1296590)

  • 1. Hepatic arterial infusion of floxuridine in patients with liver metastases from colorectal carcinoma: long-term results of a prospective randomized trial.
    Rougier P; Laplanche A; Huguier M; Hay JM; Ollivier JM; Escat J; Salmon R; Julien M; Roullet Audy JC; Gallot D
    J Clin Oncol; 1992 Jul; 10(7):1112-8. PubMed ID: 1296590
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Basic research supported developments of chemotherapy in nonresectable isolated colorectal liver metastases to a protocol of hepatic artery infusion using mitoxantrone, 5-FU + folinic acid and mitomycin C.
    Link KH; Kornmann M; Leder G; Pillasch AF; Sunelaitis E; Schatz M; Pressmar J; Beger HG
    Gan To Kagaku Ryoho; 1999 Feb; 26(3):269-81. PubMed ID: 10065089
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Randomized, multicenter trial of fluorouracil plus leucovorin administered either via hepatic arterial or intravenous infusion versus fluorodeoxyuridine administered via hepatic arterial infusion in patients with nonresectable liver metastases from colorectal carcinoma.
    Lorenz M; Müller HH
    J Clin Oncol; 2000 Jan; 18(2):243-54. PubMed ID: 10637236
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase II trial of hepatic arterial infusion of fluorouracil and recombinant human interferon alfa-2b for liver metastases of colorectal cancer refractory to systemic fluorouracil and leucovorin.
    Patt YZ; Hoque A; Lozano R; Pozdur R; Chase J; Carrasco H; Chuang V; Delpassand ES; Ellis L; Curley S; Roh M; Jones DV
    J Clin Oncol; 1997 Apr; 15(4):1432-8. PubMed ID: 9193336
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Extrahepatic biliary stenoses after hepatic arterial infusion (HAI) of floxuridine (FUdR) for liver metastases from colorectal cancer.
    Aldrighetti L; Arru M; Ronzoni M; Salvioni M; Villa E; Ferla G
    Hepatogastroenterology; 2001; 48(41):1302-7. PubMed ID: 11677951
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Selective intra-arterial chemotherapy with floxuridine as second- or third-line approach in patients with unresectable colorectal liver metastases.
    Samaras P; Breitenstein S; Haile SR; Stenner-Liewen F; Heinrich S; Feilchenfeldt J; Renner C; Knuth A; Pestalozzi BC; Clavien PA
    Ann Surg Oncol; 2011 Jul; 18(7):1924-31. PubMed ID: 21207165
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hepatic arterial floxuridine and leucovorin for unresectable liver metastases from colorectal carcinoma. New dose schedules and survival update.
    Kemeny N; Seiter K; Conti JA; Cohen A; Bertino JR; Sigurdson ER; Botet J; Chapman D; Mazumdar M; Budd AJ
    Cancer; 1994 Feb; 73(4):1134-42. PubMed ID: 8313315
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I/II study of hepatic arterial therapy with floxuridine and dexamethasone in combination with intravenous irinotecan as adjuvant treatment after resection of hepatic metastases from colorectal cancer.
    Kemeny N; Jarnagin W; Gonen M; Stockman J; Blumgart L; Sperber D; Hummer A; Fong Y
    J Clin Oncol; 2003 Sep; 21(17):3303-9. PubMed ID: 12947066
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase I trial of hepatic arterial infusion (HAI) of floxuridine with modified oxaliplatin, 5-fluorouracil and leucovorin (m-FOLFOX6) in Chinese patients with unresectable liver metastases from colorectal cancer.
    Li C; Gu Y; Zhao M; Yuan Y; Wang F; Wang Z; Li W; Luo H; Chen C; Chen G; Ding P; Wu X; Lu Z; Pan Z; Xu R; He Y; Wan D; Li Y
    Cancer Chemother Pharmacol; 2014 Nov; 74(5):1079-87. PubMed ID: 25217393
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Continuous delivery of venous 5-fluorouracil and arterial 5-fluorodeoxyuridine for hepatic metastases from colorectal cancer: feasibility and tolerance in a randomized phase II trial comparing flat versus chronomodulated infusion.
    Focan C; Levi F; Kreutz F; Focan-Henrard D; Lobelle JP; Adam R; Dallemagne B; Jehaes C; Markiewicz S; Weerts J; Bismuth H; Jasmin C; Misset JL
    Anticancer Drugs; 1999 Apr; 10(4):385-92. PubMed ID: 10378673
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Intra-arterial (5-FU/FA and FUDR) versus systemic chemotherapy (5-FU/FA) of non-resectable colorectal liver metastases].
    Gassel HJ; Müller HH; Mattes P; Stieger R; Schramm H; Lorenz M
    Langenbecks Arch Chir Suppl Kongressbd; 1998; 115():1458-60. PubMed ID: 9931911
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase I trial of systemic oxaliplatin combination chemotherapy with hepatic arterial infusion in patients with unresectable liver metastases from colorectal cancer.
    Kemeny N; Jarnagin W; Paty P; Gönen M; Schwartz L; Morse M; Leonard G; D'Angelica M; DeMatteo R; Blumgart L; Fong Y
    J Clin Oncol; 2005 Aug; 23(22):4888-96. PubMed ID: 16009951
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sequential intrahepatic fluorodeoxyuridine and systemic fluorouracil plus leucovorin for the treatment of metastatic colorectal cancer confined to the liver.
    O'Connell MJ; Nagorney DM; Bernath AM; Schroeder G; Fitzgibbons RJ; Mailliard JA; Burch P; Bolton JS; Colon-Otero G; Krook JE
    J Clin Oncol; 1998 Jul; 16(7):2528-33. PubMed ID: 9667274
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hepatic arterial infusion of floxuridine and dexamethasone plus high-dose Mitomycin C for patients with unresectable hepatic metastases from colorectal carcinoma.
    Kemeny N; Eid A; Stockman J; Gonen M; Schwartz L; Tetzlaff E; Paty P
    J Surg Oncol; 2005 Aug; 91(2):97-101. PubMed ID: 16028279
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Downstaging by regional chemotherapy of non-resectable isolated colorectal liver metastases.
    Link KH; Pillasch J; Formentini A; Sunelaitis E; Leder G; Safi F; Kornmann M; Beger HG
    Eur J Surg Oncol; 1999 Aug; 25(4):381-8. PubMed ID: 10419708
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hepatic arterial infusion of chemotherapy after resection of hepatic metastases from colorectal cancer.
    Kemeny N; Huang Y; Cohen AM; Shi W; Conti JA; Brennan MF; Bertino JR; Turnbull AD; Sullivan D; Stockman J; Blumgart LH; Fong Y
    N Engl J Med; 1999 Dec; 341(27):2039-48. PubMed ID: 10615075
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reappraisal of hepatic arterial infusion in the treatment of nonresectable liver metastases from colorectal cancer.
    ; Piedbois P; Buyse M; Kemeny N; Rougier P; Carlson R; Allen-Mersh T; O'Connell M; Chang A; Sondak V; Kemeny M; Levy E
    J Natl Cancer Inst; 1996 Mar; 88(5):252-8. PubMed ID: 8614003
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase I trial of adjuvant hepatic arterial infusion (HAI) with floxuridine (FUDR) and dexamethasone plus systemic oxaliplatin, 5-fluorouracil and leucovorin in patients with resected liver metastases from colorectal cancer.
    Kemeny N; Capanu M; D'Angelica M; Jarnagin W; Haviland D; Dematteo R; Fong Y
    Ann Oncol; 2009 Jul; 20(7):1236-41. PubMed ID: 19233901
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevention of extrahepatic disease during intraarterial floxuridine of colorectal liver metastases by simultaneous systemic 5-fluorouracil treatment? A prospective multicenter study.
    Lorenz M; Hottenrott C; Inglis R; Kirkowa-Reimann M
    Gan To Kagaku Ryoho; 1989 Dec; 16(12):3662-71. PubMed ID: 2531992
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hepatic arterial infusion versus systemic therapy for hepatic metastases from colorectal cancer: a randomized trial of efficacy, quality of life, and molecular markers (CALGB 9481).
    Kemeny NE; Niedzwiecki D; Hollis DR; Lenz HJ; Warren RS; Naughton MJ; Weeks JC; Sigurdson ER; Herndon JE; Zhang C; Mayer RJ
    J Clin Oncol; 2006 Mar; 24(9):1395-403. PubMed ID: 16505413
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.